Durable complete response to PET-CT driven stereotactic radiation therapy plus pembrolizumab for pleomorphic Pancoast cancer: Case report and literature review

Alessandra Castelluccia; Angela Sardaro; Artor Niccoli Asabella; Antonio Rosario Pisani; Dino Rubini; Maurizio Portaluri; Francesco Tramacere

doi:10.1002/ccr3.8633

Durable complete response to PET-CT driven stereotactic radiation therapy plus pembrolizumab for pleomorphic Pancoast cancer: Case report and literature review

Clin Case Rep. 2024 Apr 5;12(4):e8633. doi: 10.1002/ccr3.8633. eCollection 2024 Apr.

Authors

Alessandra Castelluccia¹, Angela Sardaro², Artor Niccoli Asabella³, Antonio Rosario Pisani³, Dino Rubini⁴, Maurizio Portaluri¹, Francesco Tramacere¹

Affiliations

¹ Department of Radiotherapy "A. Perrino" Hospital Brindisi Italy.
² Section of Radiology and Radiation Oncology, Interdisciplinary Department of Medicine University of Bari "Aldo Moro" Bari Italy.
³ Section of Nuclear Medicine, Interdisciplinary Department of Medicine University of Bari Aldo Moro Bari Italy.
⁴ Department of Precision Medicine Università degli Studi della Campania Luigi Vanvitelli Napoli Campania Italy.

Abstract

PET-driven SBRT plus pembrolizumab as first-line therapy against pleomorphic Pancoast cancer appears beneficial, probably due to high equivalent doses of SBRT on photopenic necrotic core and synergic immune system stimulation of immunoradiotherapy.

Keywords: Pancoast tumor; image‐guided radiation therapy; immune checkpoint inhibitors; pleomorphic lung cancer; radioimmunotherapy; stereotactic body radiotherapy.

Publication types

Case Reports